According to Ipsen's press release, the interim data from the long-term open-label ELATIVE study, which included over three years of follow-up with 115 patients suffering from primary biliary cholangitis (PBC), demonstrate that Iqirvo enables sustainable improvements in cholestasis biomarkers and stabilization of fibrosis markers. At week 182, 72% of patients treated with Iqirvo showed a sustained biochemical response, with a 47% reduction in alkaline phosphatase levels compared to baseline.
Improvements in Symptoms
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The results from the ELATIVE trial also indicate that patients experiencing moderate to severe fatigue observed an improvement in their symptoms, and similar outcomes were noted for pruritus. These positive effects are accompanied by a favorable long-term tolerance profile, with no new safety concerns, according to the press release.
Potential Role in Mitochondrial Function
The new data from the ELATIVE trial suggest that Iqirvo, a PPAR ?/? receptor agonist, could play a significant role in improving pathways associated with fatigue and mitochondrial function. Iqirvo is currently approved for the treatment of PBC in combination with ursodeoxycholic acid in adults with inadequate response or as monotherapy in patients intolerant to UDCA, in several regions, including the United States and the EU.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
